Mydecine Innovations Group (MYCO) Announces MYCO-001 Seamless Phase 2/3 Smoking Cessation Clinical Trial
New York bill would create a psychedelics research institute to study psilocybin treatment for substance use disorder and depression.
New York Bill Would Create State-Sponsored Psychedelics Research Institute
A new bill proposed in New York would create a psychedelic research institute to study the effect of psilocybin, LSD, MDMA, and ibogaine on conditions including addictive disorders, depression, PTSD, and end-of-life anxiety. The bill is sponsored by Assemblywoman Linda Rosenthal (D), who believes that “psychedelics provide a host of benefits without the same risk of overdose or dependency that other medications may provide”. The legislature suggests that “psilocybin is a breakthrough therapy for severe depression and nicotine addiction” and may also provide treatment for methamphetamine or opioid addiction.
Johns Hopkins study found that psilocybin is more effective at treating nicotine addiction than the leading drug, with 80% quitting after single dose
More Than A Trip: Psychedelic Drugs Being Used To Help People Quit Smoking In Just One Dose
A study at Johns Hopkins Behavioral Biology Research Center found that 80% of participants were able to quit smoking for at least six months after taking one dose of psilocybin, including one participant who was a heavy smoker for over 25 years. This suggests that psilocybin therapy is over twice as effective as the leading smoking cessation drug, varenicline, which has a 35% success rate after six months. Dr. Albert Garcia-Romeu explains that psilocybin is effective for treating addiction because it changes the way the brain makes connections, which can “interrupt old patterns, well-worn neuro pathways, or habits.”